Zoryve (roflumilast) is a prescription drug that’s used to treat plaque psoriasis, atopic dermatitis, and seborrheic dermatitis in adults and certain children. Zoryve comes as a topical cream or ...

The investigational ZORYVE foam 0.3% shows significant improvements in patient-reported quality of life and symptom relief for individuals with psoriasis, indicating its potential as a valuable ...

Arcutis is a rare topical dermatology player with accelerating launch metrics and continued growth. Read more about the ...

Poster Number 62155 Roflumilast Foam 0.3% in Patients With Scalp and Body Psoriasis: Improvements in Patient-Reported Outcomes (ARRECTOR) Gooderham, M et al. ZORYVE cream, 0.3%, is indicated for ...

Vtama and Zoryve have different mechanisms of action, but are lumped together into the newer novel agents class that are indicated for all levels of severity in psoriasis. Unlike traditional ...

and roflumilast (Zoryve). Practicing at a referral center, Paolo Romanelli, MD, of the University of Miami, does not see as many cases of mild/moderate psoriasis as community dermatologists.

The cost of Zoryve can vary based on several factors, including the form you take and your insurance coverage. Coupons and drug savings programs can lower the price you’ll pay for Zoryve.

The third risk to consider would be in terms of the sNDA that was submitted to the FDA for the expansion of the label of ZORYVE foam to treat patients with scalp and body psoriasis. The FDA ...

Q4 2024 net product revenue for ZORYVE® (roflumilast) was $69.4 million, a 413% increase compared to Q4 of 2023 and a 55% increase compared to Q3 of 2024; driven by strong portfolio demand growth ...

ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older. ZORYVE cream, 0.15% ...

ZORYVE foam significantly improved quality ... Individuals reported an improvement in symptoms as well as a reduction in how psoriasis impacted their daily life (e.g., embarrassment, stress ...

A second poster presentation shares results from the Phase 3 ARRECTOR trial that outlines improvements in patient-reported outcomes with investigational ZORYVE foam 0.3% compared with vehicle in ...